Roche Holding AG

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

Pfizer's Hympavzi, a once-weekly injection, received US approval for treating hemophilia A or B in patients aged 12 and older without inhibitors, costing $795,600 annually. It aims to reduce bleeding episodes and may offer convenience for hemophilia B patients. Despite modest commercial potential, it could carve out a niche in hemophilia B treatment.

E. Heath reports advisory/consulting, steering committee, honoraria/paid travel, speaker’s bureau, and research support from various companies. J.R. Ribeiro, K. Poorman, and J. Xiu report personal fees and other support from Caris Life Sciences. H. Mamdani reports other support and grants from Daiichi Sankyo, AstraZeneca, and Genentech. A.F. Shields reports personal fees from Caris Life Sciences. G.L. Lopes reports stock ownership, honoraria, consulting, research funding, travel, and other relationships with multiple companies. S.A. Kareff reports personal fees and travel grants from various organizations. M. Radovich and G.W. Sledge report other support from Caris Life Sciences. G.A. Vidal reports relationships with Guardant360, Gilead, BillionToOne, Genentech/Roche, GSK, and AstraZeneca. J.L. Marshall reports personal fees from Caris. No other disclosures were reported by the other authors.

Global LAG-3 Inhibitors Market expected to exceed USD 3 billion by 2029; Opdualag, first LAG-3 therapy, approved for melanoma. LAG-3 inhibitors show potential in combination therapies for various cancers and diseases. Key players include Bristol Myers Squibb, Roche, and Regeneron. Market valued at USD 625 million in 2023, projected to grow significantly.

Global LAG-3 inhibitors market to exceed USD 3 billion by 2029, driven by the approval of Opdualag, the first LAG-3 therapy, and ongoing clinical trials evaluating LAG-3 inhibitors in combination therapies. Key players include Bristol Myers Squibb, Symphogen A/S, and Hoffmann-La Roche.

Bispecific antibodies market highlights include >30 development platforms, >USD 8B market size in 2023, and >800 clinical trials. Key approved antibodies like Blincyto and Hemlibra have seen significant sales. The market is driven by innovations in immuno-oncology, with ongoing trials by major pharma companies and research institutions globally.

Bispecific antibodies, designed to target two antigens simultaneously, are revolutionizing cancer treatment by enhancing antitumor immune responses and overcoming immune evasion mechanisms. The global market for these antibodies is projected to exceed USD 8 billion by 2023, driven by advancements in antibody engineering and increasing demand for targeted therapies. Major pharmaceutical companies are investing in bispecific antibody research, with strategic collaborations accelerating development. The market is expected to grow further due to expanding therapeutic applications and a shift towards personalized medicine.

CEACAM5 drugs market to grow significantly due to rising cancer diagnoses and clinical trials; no CEACAM5 drugs currently approved. Key companies developing CEACAM5 drugs include Merck KGaA, Sanofi, and Roche. Emerging therapies like SGM-101 and M9140 show promise in clinical trials.

DelveInsight's 'Spinal Muscular Atrophy Pipeline Insight, 2024' report details 18+ companies developing 20+ therapies, including key players like Scholar Rock, Biogen, and Roche. The report covers clinical trials, MOA, ROA, recent developments, and emerging therapies like ACTX-401, Apitegromab, and GYM329, expected to impact the SMA market.